Startups
ADmit Therapeutics
Biotechnology company developing blood-based prognostic tests for neurodegenerative disease. Its MAP-AD test combines mitochondrial DNA methylation biomarkers, sequencing and machine learning with clinical risk factors to estimate whether a patient with mild cognitive impairment will progress to Alzheimer’s dementia. The test supports patient stratification and clinical-trial selection. MAP-AD obtained CE-IVDR marking in 2025; the company also operates a CAP-accredited, CLIA-certified laboratory.
Founded 2017
Team
Alfred Fu Kong LuiLaboratory Director |
Carla TraperoProject Manager, PRRC and Technical Manager |
Courosh MehanianScientific Advisor |
Ferran PratChairman of the Board |
 Howard FillitBoard Observer |
Jordi GascónCo-Founder and Medical Advisor |
Jose Luis MosqueraDirector of Artificial Intelligence and Data Science |
Maite FiblaBoard Member |
Marta BarrachinaCo-Founder, CEO and Board Member |
Marta BlanchLaboratory Technical Supervisor |
Miguel ViribayBusiness Development Director |
Pau MartíBioinformatician |
Ramón ReñéCo-Founder and Medical Advisor |
Russell SwerdlowScientific Advisor |
Santiago LozanoBoard Member |
Víctor FuentesQuality Manager |